Trials / Unknown
UnknownNCT00559221
FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML
Fludarabine and Cytarabine as Continuous Infusion Plus Idarubicin With Granulocyte-Colony Stimulating Factor (G-CSF) Priming for Patients Younger Than 60 Years With Resistant Acute Myeloid Leukemia
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 37 (estimated)
- Sponsor
- Cooperative Study Group A for Hematology · Network
- Sex
- All
- Age
- 15 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
\- To determine the feasibility of fludarabine and cytarabine as continuous infusion plus idarubicin with granulocyte-colony stimulating factor priming for patients with resistant acute myeloid leukemia other than acute promyelocytic leukemia
Detailed description
\- The feasibility will be evaluated in terms of toxicities, complete remission rate, duration of complete remission, disease-free survival, and overall survival.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FLAG+IDA | Fludarabine, cytarabine, G-CSF |
Timeline
- Start date
- 2004-12-01
- Completion
- 2008-06-01
- First posted
- 2007-11-16
- Last updated
- 2008-10-15
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00559221. Inclusion in this directory is not an endorsement.